Sunshine Biopharma logo

Sunshine BiopharmaNASDAQ: SBFM

Profile

Sector:

Healthcare

Country:

United States

IPO:

15 February 2022

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$5.60 M
-91%vs. 3y high
13%vs. sector
-vs. 3y high
-vs. sector
-99%vs. 3y high
22%vs. sector
-99%vs. 3y high
5%vs. sector

Price

after hours | Fri, 01 Nov 2024 23:58:49 GMT
$2.80-$0.02(-0.71%)

Dividend

No data over the past 3 years
$9.30 M$11.80 M
$9.30 M-$494.30 K

Analysts recommendations

Institutional Ownership

SBFM Latest News

Sunshine Biopharma Launches Two New Generic Prescription Drugs
accesswire.com26 September 2024 Sentiment: POSITIVE

FORT LAUDERDALE, FL / ACCESSWIRE / September 26, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched two new generic prescription drugs. The first product is Varenicline, a generic version of Champix®.

Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry
accesswire.com04 September 2024 Sentiment: POSITIVE

Current Test Positivity Rate for Coronavirus Infection in the U.S. is 18% Development of a novel antiviral compound, XR8-23 (Compound 10), targeting SARS-CoV-2 papain-like protease (PLpro) with both submicromolar potency and animal model efficacy XR8-23 (Compound 10) showed significant drug accumulation in lung of mice and favorable pharmacokinetic properties Research was conducted in collaboration with the University of Arizona FORT LAUDERDALE, FL / ACCESSWIRE / September 4, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced the publication of new research results in the Journal of Medicinal Chemistry. The published data demonstrate a novel PLpro inhibitor with submicromolar potency and in vivo efficacy in a mouse model of SARS-CoV-2 infection.

Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada
accesswire.com26 August 2024 Sentiment: POSITIVE

FORT LAUDERDALE, FL / ACCESSWIRE / August 26, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has launched nine (9) new generic prescription drugs year-to-date. These launches bring the total number of drugs that the Company has on the market in Canada to sixty-one (61).

Why Is Sunshine Biopharma (SBFM) Stock Down 17% Today?
InvestorPlace04 March 2024 Sentiment: NEGATIVE

Sunshine Biopharma (NASDAQ: SBFM ) stock is falling on Monday after the pharmaceutical company received a delisting notice from the Nasdaq Exchange. That delisting notice notes that shares of SBFM stock have been trading for less than the $1 minimum bid price for too long.

SBFM Stock Alert: Why Sunshine Biopharma Is Down 28% Today
InvestorPlace12 May 2023 Sentiment: NEGATIVE

Sunshine Biopharma (NASDAQ: SBFM ) stock is falling on Friday after the pharmaceutical company revealed details of a private offering for its shares. Sunshine Biopharma has agreed to sell 5,952,381 units and pre-funded units at a purchase price of 84 cents per unit to a single healthcare-focused institutional investor.

SBFM Stock Alert: Why Sunshine Biopharma Is Up 80% Today
InvestorPlace11 May 2023 Sentiment: POSITIVE

Canadian biotech company Sunshine Biopharma (NASDAQ: SBFM ) is among the leaders in today's rather volatile session. Currently, shares of SBFM stock are up more than 60% after the company announced what appears to be incredible earnings.

What type of business is Sunshine Biopharma?

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is based in Fort Lauderdale, Florida.

What sector is Sunshine Biopharma in?

Sunshine Biopharma is in the Healthcare sector

What industry is Sunshine Biopharma in?

Sunshine Biopharma is in the Drug Manufacturers - Specialty & Generic industry

What country is Sunshine Biopharma from?

Sunshine Biopharma is headquartered in United States

When did Sunshine Biopharma go public?

Sunshine Biopharma initial public offering (IPO) was on 15 February 2022

What is Sunshine Biopharma website?

https://sunshinebiopharma.com

Is Sunshine Biopharma in the S&P 500?

No, Sunshine Biopharma is not included in the S&P 500 index

Is Sunshine Biopharma in the NASDAQ 100?

No, Sunshine Biopharma is not included in the NASDAQ 100 index

Is Sunshine Biopharma in the Dow Jones?

No, Sunshine Biopharma is not included in the Dow Jones index

When was Sunshine Biopharma the previous earnings report?

No data

When does Sunshine Biopharma earnings report?

The next expected earnings date for Sunshine Biopharma is 13 November 2024